Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cellectar BiosciencesCLRB +0.85%25 Days Sales Outstanding is 0.00 as of Jun. 2026. GuruFocus rates CLRB with a GF Score™ of 25/100. The stock has 1 warning sign investors should review. Among 841 Biotechnology companies, Cellectar Biosciences ranks worse than 118905.95% on this metric.
The historical rank and industry rank for Cellectar Biosciences's Days Sales Outstanding or its related term are showing as below:
CLRB's Days Sales Outstanding is not ranked *
in the Biotechnology industry.
Industry Median: 68.94 * Ranked among companies with meaningful Days Sales Outstanding only.
Cellectar Biosciences's Days Sales Outstanding
stayed the same
from Jun. 2025 (0.00) to Jun. 2026 (0.00).
Cellectar Biosciences (NAS:CLRB) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Cellectar Biosciences Days Sales Outstanding Related Terms
Cellectar Biosciences Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Cellectar Biosciences's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellectar Biosciences Days Sales Outstanding Chart
CLRB vs ENLV, TVRD, PVCT: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Cellectar Biosciences's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellectar Biosciences Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cellectar Biosciences's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Cellectar Biosciences's Days Sales Outstanding falls into.
Cellectar Biosciences Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellectar Biosciences (CLRB) has a Days Sales Outstanding of 0.00 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Cellectar Biosciences and its competitors. According to the industry distribution chart, Cellectar Biosciences ranks #999999 out of 841 companies in the Biotechnology industry.
Is Cellectar Biosciences' Days Sales Outstanding too high?
Cellectar Biosciences' current Days Sales Outstanding is 0.00. Based on the distribution chart, Cellectar Biosciences ranks #999999 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cellectar Biosciences has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Cellectar Biosciences' Days Sales Outstanding compare to ENLV and TVRD?
According to the Biotechnology industry distribution chart, Cellectar Biosciences ranks #999999 out of 841 companies for Days Sales Outstanding. This places Cellectar Biosciences in the lower half of its industry. The industry median Days Sales Outstanding is 68.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Cellectar Biosciences and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cellectar Biosciences's current Days Sales Outstanding is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellectar Biosciences stock overvalued right now?
Cellectar Biosciences (CLRB) has a current Days Sales Outstanding of 0.00. The current Days Sales Outstanding is 0.00. Cellectar Biosciences' overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Cellectar Biosciences (CLRB), the current Days Sales Outstanding is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
25GF Score
Get the complete analysis for CLRB
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLRB has been successfully added to your 
